# US 2025/0084048 A1 · Pi3k-alpha inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084048 A1
- Document ID: US20250084048A1
- Status: Published application
- Kind: A1
- Application number: 18/698,690
- Filed: 2022-10-07
- Published: 2025-03-13
- Earliest claimed: 2021-10-07
- Assignees: Relay Therapeutics, Inc.
- Applicants: Relay Therapeutics, Inc.
- Inventors: Alessandro BOEZIO; Alexander M. TAYLOR; Junyi ZHANG; Kelley c. SHORTSLEEVES; Levi Charles Thomas PIERCE; Thomas H. MCLEAN; Anna KAPLAN; Amaël MADEC; Brandi M. HUDSON; Jun MA; Yue PAN; Gaetan MAERTENS; Johanne OUTIN
- Web page: https://patentgrep.com/patent/US20250084048A1

## CPC

- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/536: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 35/00: Antineoplastic agents
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 239/88: Oxygen atoms
- C07D 239/91: with aryl or aralkyl radicals attached in position 2 or 3
- C07D 239/95: with hetero atoms directly attached in positions 2 and 4
- C07D 311/22: with oxygen or sulfur atoms directly attached in position 4
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3Ka enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3Ka signaling with the compounds and compositions of the disclosure.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X is CH, C(RX), NH, or N(RX);
Y is O, CH, C(RY), N, NH, or N(RY);
Z is C or N;
G1 is CH, N, or C—RG1;
G2 is CH, N, or C—RG2;
one of G3 or G4 is C—R2 and the other is CH, N, or C—RG3;
R1 is -L1-R1A;
R2 is -L2-R2A;
RG1 is -LG1-RG1A;
RG2 is -LG2-RG2A;
RG3 is -LG3-RG3A;
RX is -LX-RXA;
RY is -LY-RYA;
each of L1, L2, LG1, LG2, LG3, LX, and LY is independently a covalent bond, or a C1-4 bivalent saturated or unsaturated, straight or branched hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —CH(RL)—, —C(RL)2—, C3-6 cycloalkylene, C3-6 heterocycloalkylene, —N(R)—, —N(R)C(O)—, —N(R)C(NR)—, —N(R)C(NOR)—, —N(R)C(NCN)—, —C(O)N(R)—, —N(R)S(O)2—, —S(O)2N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)—, or —S(O)2—;
R1A is RA or RB substituted by r1 instances of R1C;
R2A is -CyA-RCyA substituted by r2 instances of R2C;
RG1A is RA or RB substituted by r3 instances of RG1C;
RG2A is RA or RB substituted by r4 instances of RG2C;
RG3A is RA or RB substituted by r5 instances of RG3C;
RXA is RA or RB substituted by r6 instances of RXC;
RYA is RA or RB substituted by r7 instances of RYC;
RL is RA or RB substituted by r7 instances of RLC;
CyA is a phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
RCyA is RA or RB; or RCyA and R2C are taken together with their intervening atoms to form a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 3-7 membered partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each instance of RA is independently oxo, deuterium, halogen, —CN, —NO2, —OR, —SF5, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)2F, —S(O)R, —S(O)NR2, —S(O)(NR)R, —S(O)(NCN)R, —S(NCN)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —P(O)R2, —P(O)(R)OR, or —B(OR)2;
each instance of RB is independently a C1-6 aliphatic chain; phenyl; naphthyl; cubanyl; adamantyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring; a 5-12 membered saturated or partially unsaturated bicyclic carbocyclic ring; a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each instance of R1C, R2C, RG1C, RG2C, RG3C, RXC, RYC, and RLC is independently oxo, deuterium, halogen, —CN, —NO2, —OR, —SF5, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)2F, —S(O)R, —S(O)NR2, —S(O)(NR)R, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, —P(O)R2, —P(O)(R)OR, —B(OR)2, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
each instance of R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or
two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and
each of r1, r2, r3, r4, r5, r6, r7, and r7 is independently 0, 1, 2, 3, or 4.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is a compound of formula II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Y is O or N.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Z is C.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is CH, C(RX), or N(RX).

### Claim at position 8

-16. (canceled)

### Claim 17 (depends on 1)

The compound of claim 1, wherein LG2 is a covalent bond or —O—.

### Claim 18 (depends on 1)

The compound of claim 1, wherein RG2A is RB substituted by r4 instances of RG2C.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The compound of claim 1, wherein RG2 is methyl.

### Claim 21 (depends on 1)

The compound of claim 1, wherein L1 is a covalent bond.

### Claim 22 (depends on 1)

The compound of claim 1, wherein R1A is a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R1A is substituted by r1 instances of R1C.

### Claim at position 15

-24. (canceled)

### Claim 25 (depends on 1)

The compound of claim 1, wherein each instance of R1C is independently halogen, —CN, —O—(C1-6 aliphatic), or C1-6 aliphatic; wherein each C1-6 aliphatic is optionally substituted with one or more halogen atoms.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The compound of claim 1, wherein R2 is —CH(CH3)N(R)—R2A, —CH(RL)N(H)—R2A, —CH(CH3)N(H)—R2A, or —R2A.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The compound of claim 1, wherein CyA is phenyl; naphthyl; a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

### Claim 30 (depends on 1)

The compound of claim 1, wherein R2A is

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The compound of claim 1, wherein each instance of R2C is independently halogen, —OH, —C(O)OR, —C(O)NR2, —S(O)R, —S(O)2R, —S(O)NR2, —S(O)2NR2, or an optionally substituted C1-6 aliphatic.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The compound of claim 1, wherein RCyA is halogen, oxo, —OH, or —C(O)OR.

### Claim 35 (depends on 1)

The compound of claim 1, wherein RXA is RB substituted by r6 instances of RXC, or RXA is a C1-6 aliphatic chain or phenyl substituted by r6 instances of RXC.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The compound of claim 1, wherein RX is methyl.

### Claim 38

A compound selected from those set forth in Table 1 or Table 2, or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 1)

A pharmaceutical composition, comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim at position 31

-41. (canceled)

### Claim 42 (depends on 1)

A method of inhibiting PI3Kα signaling activity, treating a PI3Kα-mediated disorder, or treating a cellular proliferative disease in a subject, comprising administering a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, to the subject in need thereof.

### Claim at position 33

-47. (canceled)
